Protective and anti-angiopathy effects of caffeic acid phenethyl ester against induced type 1 diabetes in vivo

• Published in: International immunopharmacology 2013-10, Vol.17 (2), p.408-414
• Main Authors: Abduljawad, Soha H., El-Refaei, Mohamed F., El-Nashar, Nermeen N.
• Format: Article
• Language: English
• Subjects: Angiostatic and CAPE; Animals; Anti-angiopathy; Anti-diabetic; Anti-inflammatory; Blood Glucose - metabolism; Caffeic Acids - administration & dosage; Cells, Cultured; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - immunology; Endostatins - blood; Humans; Insulin - blood; Interferon-gamma - metabolism; Interleukin-1beta - metabolism; Islets of Langerhans - metabolism; Islets of Langerhans - pathology; Male; Matrix Metalloproteinase 9 - metabolism; Mice; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - immunology; Nitric Oxide - metabolism; Phenylethyl Alcohol - administration & dosage; Phenylethyl Alcohol - analogs & derivatives; Vesicular Transport Proteins - metabolism
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2013.06.019

This study aims at investigating the anti-diabetic effects of caffeic acid phenethyl ester (CAPE) against induced immunoregulated diabetes in vivo. Swiss mice were administered cyclosporine (CsA) 20mg/kg/day, s.c. for 10days and simultaneously received multiple low doses of streptozotocin (MLDSTZ) 40mg/kg/day, i.p. for 5 consecutive days. Our results showed that administering CAPE (5μM/kg i.p./every 2days) to diabetic mice led to a time-dependent decrease in blood glucose levels to 137.1±7.2 from 229.1±12.6mg/dl and induced a significant increase in serum insulin levels by 93.8% compared with untreated ones. An in vivo anti-inflammatory effect of CAPE treated diabetic mice was observed, based on a significant decrease in IL-1β and IFN-γ (P